Trial site
Oncology Hematology Care
Cincinnati, Ohio 45242, United StatesNot linked to an institution yet
- 15running trials
- 7closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 28 trials
- Phase 12 trials
- Status
- Recruiting8 trials
- Active, not recruiting6 trials
- Completed4 trials
- Withdrawn2 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- SCRI Development Innovations, LLC3 trials
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company2 trials
- TScan Therapeutics, Inc.2 trials
- Allotera Therapeutics1 trial
- and 9 more
Running trials
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910· Phase 2· SCRI Development Innovations, LLC· Source
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276· Phase 3· Bristol-Myers Squibb· Source
Contact: Patrick Ward, Site 0284
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794· Phase 2· Allotera Therapeutics· Source
Contact: Doug Hart
Recruiting
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
NCT06634394· Phase 1· Aptevo Therapeutics· Source
Contact: Research Coordinator
Active, not recruiting
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487· Phase 1· TScan Therapeutics, Inc.· Source
Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Contact: Kruti Patel, Site 0054
Recruiting
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135· Phase 2· SCRI Development Innovations, LLC· Source
Contact: Sarah Cannon Development Innovations, LLC
Active, not recruiting
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027· TScan Therapeutics, Inc.· Source
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source
Contact: Iovance Biotherapeutics Study Team
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Enrolling by invitation
Long-Term Follow-up Study
NCT05332054· Caribou Biosciences, Inc.· Source
Active, not recruiting
Avelumab Program Rollover Study
NCT03815643· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Active, not recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· Phase 3· Eisai Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Recruiting
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786· Phase 2· SCRI Development Innovations, LLC· Source
Contact: Sarah Cannon Development Innovations, LLC
Withdrawn
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
NCT06205290· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Completed
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
NCT04083976· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
NCT03901963· Phase 3· Janssen Research & Development, LLC· Source
Terminated
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
NCT03646123· Phase 2· Seagen Inc.· Source
Completed
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· Phase 3· pharmaand GmbH· Source
Report an error